Literature DB >> 16301627

Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Cary Hsu1, Marybeth S Hughes, Zhili Zheng, Regina B Bray, Steven A Rosenberg, Richard A Morgan.   

Abstract

IL-15 is a common gamma-chain cytokine that has been shown to be more active than IL-2 in several murine cancer immunotherapy models. Although T lymphocytes do not produce IL-15, murine lymphocytes carrying an IL-15 transgene demonstrated superior antitumor activity in the immunotherapy of B16 melanoma. Thus, we sought to investigate the biological impact of constitutive IL-15 expression by human lymphocytes. In this report we describe the generation of a retroviral vector encoding a codon-optimized IL-15 gene. Alternate codon usage significantly enhanced the translational efficiency of this tightly regulated gene in retroviral vector-transduced cells. Activated human CD4+ and CD8+ human lymphocytes expressed IL-15Ralpha and produced high levels of cytokine upon retroviral transduction with the IL-15 vector. IL-15-transduced lymphocytes remained viable for up to 180 days in the absence of exogenous cytokine. IL-15 vector-transduced T cells showed continued proliferation after cytokine withdrawal and resistance to apoptosis while retaining specific Ag recognition. In the setting of adoptive cell transfer, IL-15-transduced lymphocytes may prolong lymphocyte survival in vivo and could potentially enhance antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301627      PMCID: PMC1473971          DOI: 10.4049/jimmunol.175.11.7226

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  IL-15R alpha expression on CD8+ T cells is dispensable for T cell memory.

Authors:  Patrick R Burkett; Rima Koka; Marcia Chien; Sophia Chai; Faye Chan; Averil Ma; David L Boone
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

Review 2.  IL-15 in the life and death of lymphocytes: immunotherapeutic implications.

Authors:  Thomas A Waldmann
Journal:  Trends Mol Med       Date:  2003-12       Impact factor: 11.951

3.  IL-15 promotes the survival of naive and memory phenotype CD8+ T cells.

Authors:  Marion Berard; Katja Brandt; Silvia Bulfone-Paus; David F Tough
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

4.  Vienna RNA secondary structure server.

Authors:  Ivo L Hofacker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

5.  Effects of codon-optimization on protein expression by the human herpesvirus 6 and 7 U51 open reading frame.

Authors:  Birgit G Bradel-Tretheway; Zhu Zhen; Stephen Dewhurst
Journal:  J Virol Methods       Date:  2003-08       Impact factor: 2.014

6.  A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies.

Authors:  Angel Cid-Arregui; Victoria Juárez; Harald zur Hausen
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

Authors:  Renier J Brentjens; Jean-Baptiste Latouche; Elmer Santos; Francesc Marti; Michael C Gong; Clay Lyddane; Philip D King; Steven Larson; Mark Weiss; Isabelle Rivière; Michel Sadelain
Journal:  Nat Med       Date:  2003-02-10       Impact factor: 53.440

8.  Codon optimization reveals critical factors for high level expression of two rare codon genes in Escherichia coli: RNA stability and secondary structure but not tRNA abundance.

Authors:  Xiaoqiu Wu; Hans Jörnvall; Kurt D Berndt; Udo Oppermann
Journal:  Biochem Biophys Res Commun       Date:  2004-01-02       Impact factor: 3.575

Review 9.  Adoptive-cell-transfer therapy for the treatment of patients with cancer.

Authors:  Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

10.  Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.

Authors:  Ke Liu; Steven A Rosenberg
Journal:  J Immunother       Date:  2003 May-Jun       Impact factor: 4.456

View more
  43 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

Review 2.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

Review 3.  Development of CAR T cells designed to improve antitumor efficacy and safety.

Authors:  Janneke E Jaspers; Renier J Brentjens
Journal:  Pharmacol Ther       Date:  2017-03-22       Impact factor: 12.310

Review 4.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.

Authors:  Malcolm K Brenner; Fatma V Okur
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

6.  Characterization of human T lymphocytes engineered to express interleukin-15 and herpes simplex virus-thymidine kinase.

Authors:  Cary Hsu; John D Abad; Richard A Morgan
Journal:  J Surg Res       Date:  2013-04-03       Impact factor: 2.192

Review 7.  Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.

Authors:  Ting-Wei Yu; Ho-Yen Chueh; Ching-Chou Tsai; Cheng-Tao Lin; Jiantai Timothy Qiu
Journal:  Hum Vaccin Immunother       Date:  2016-08-25       Impact factor: 3.452

8.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors:  V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

Review 9.  Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Authors:  Yolanda Nesbeth; Jose R Conejo-Garcia
Journal:  Clin Dev Immunol       Date:  2010-11-07

Review 10.  Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

Authors:  Oladapo O Yeku; Renier J Brentjens
Journal:  Biochem Soc Trans       Date:  2016-04-15       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.